Prognostic value of YKL-40 in colorectal carcinoma patients: A meta-analysis

Table 2 Results of meta-analysis

	No. of studies	HR	95%CI	P value	I2 (%)	P value
Overall survival	8	1.80	1.32-2.45	< 0.001	90.3	< 0.001
Treatment
Surgery	7	1.99	1.27-3.12	0.003	90.8	< 0.001
Non-surgery	1	1.17	1.05-1.30	0.004	-	-
Tumor type
Colorectal carcinoma	6	1.83	1.30-2.56	< 0.001	92.9	< 0.001
Rectal carcinoma	1	0.69	0.04-11.45	0.796	-	-
Colon carcinoma	1	1.81	1.13-2.90	0.013	-	-
Source of YKL-40
Serum	6	1.83	1.26-2.66	0.001	92.7	< 0.001
Tissue	2	1.74	1.28-2.36	< 0.001	0.0	0.816
Progression-free survival	7	1.62	1.22-2.16	0.001	88.3	< 0.001
Treatment
Surgery	6	1.93	1.21-3.08	.005	87.8	< 0.001
Non-surgery	1	1.00	0.91-1.09	1.000	-	-
Tumor type
Colorectal carcinoma	6	1.64	1.22-2.20	0.001	90.2	< 0.001
Rectal carcinoma	1	1.32	0.39-4.46	0.655	-	-
Source of YKL-40
Serum	6	1.54	1.15-2.07	0.004	88.0	< 0.001
Tissue	1	2.00	1.36-2.94	< 0.001	-	-

HR: Hazard ratio; CI: Confidence interval.